Advances in Virus-Directed Therapeutics against Epstein-Barr Virus-Associated Malignancies.
Advances in Virus-Directed Therapeutics against Epstein-Barr Virus-Associated Malignancies.
复制标题
DOI：
10.1155/2012/509296
复制
发表时间：
2012
影响因子：
2.2
通讯作者：
Faller DV
中科院分区：
文献类型：
--
作者：
Ghosh SK;Perrine SP;Faller DV
EB病毒（Epstein-Barr virus，EBV）是伯基特淋巴瘤（Burkitt’s lymphoma）和鼻咽癌（nasopharyngeal carcinoma）的病原体，并且还与多种人类恶性肿瘤（包括霍奇金淋巴瘤（Hodgkin’s lymphoma）和非霍奇金淋巴瘤（non-Hodgkin’s lymphoma））、移植后淋巴组织增生性疾病以及其他组织的散发性癌症相关。EBV与这些后者恶性肿瘤的因果关系仍然存在争议，尽管这些癌症中的大多数中的附加体EBV基因组是克隆的，这表明在肿瘤发展的非常早期的感染以及EBV在这些疾病的发生中的可能作用。此外，当存在EBV时，这些肿瘤的预后总是很差，与它们的EBV阴性对应物相比。EBV在这些肿瘤中的物理存在代表了治疗方法的潜在“肿瘤特异性”靶标。虽然其他类型疱疹病毒感染的治疗选择在过去二十年中已经发展和改进，但是针对EBV的治疗已经落后。药物干预的一个主要限制是从裂解性感染转变为潜在的基因表达模式，这在与病毒相关的肿瘤中持续存在。在本文中，我们提供了一个新的病毒靶向治疗方法对EBV相关的恶性肿瘤的简要说明。
Epstein-Barr virus (EBV) is the causal agent in the etiology of Burkitt's lymphoma and nasopharyngeal carcinoma and is also associated with multiple human malignancies, including Hodgkin's and non-Hodgkin's lymphoma, and posttransplantation lymphoproliferative disease, as well as sporadic cancers of other tissues. A causal relationship of EBV to these latter malignancies remains controversial, although the episomic EBV genome in most of these cancers is clonal, suggesting infection very early in the development of the tumor and a possible role for EBV in the genesis of these diseases. Furthermore, the prognosis of these tumors is invariably poor when EBV is present, compared to their EBV-negative counterparts. The physical presence of EBV in these tumors represents a potential “tumor-specific” target for therapeutic approaches. While treatment options for other types of herpesvirus infections have evolved and improved over the last two decades, however, therapies directed at EBV have lagged. A major constraint to pharmacological intervention is the shift from lytic infection to a latent pattern of gene expression, which persists in those tumors associated with the virus. In this paper we provide a brief account of new virus-targeted therapeutic approaches against EBV-associated malignancies.